Articles tagged with Metastasis
PharmaMar and Chugai agree on an early termination of their license agreement for Zepsyre in Japan, allowing PharmaMar to regain rights to the compound. PharmaMar will receive €3,000,000 from Chugai and can now pursue new partnerships for the drug.
A University of Colorado Cancer Center study shows that combining radiosurgery with immunotherapy, especially PD-1 inhibitors, can significantly improve cancer control and overall survival in melanoma patients. The study found that patients treated with anti-PD-1 therapies had a median brain metastasis-free survival of not reached, whe...
A new smart probe developed by Tel Aviv University researchers can detect and visualize individual cancer cells in real-time, allowing surgeons to target specific tumor locations. The probe uses near-infrared technology to identify overproduced enzymes in cancer cells, guiding precise removal of malignant tissue.
University of Alberta researchers discovered 11 genes that play essential roles in cancer cell metastasis, enabling the blockage of over 99.5% of cancer metastasis in living cells. The study suggests potential therapeutic targets for preventing cancer spread.
A study led by CNIO researchers shows that silibinin reduces brain metastasis lesions in mice and patients, targeting the tumor microenvironment. The treatment has shown encouraging results, with 75% of patients reacting positively and a 15.5-month average survival rate
The ALEX trial results show alectinib achieving a median progression-free survival of 34.8 months compared to 10.9 months for crizotinib in ALK-positive non-small cell lung cancer patients. Alectinib also demonstrated an improved overall response rate and fewer side effects than crizotinib.
Weichselbaum, Professor and Chairman of Radiation and Cellular Oncology at the University of Chicago, has made significant contributions to understanding oligometastasis. His work on curing tumors through surgery or radiation therapy has been supported by several studies demonstrating successful treatments.
Researchers from University of Pennsylvania develop a mathematical model to understand the dynamics of cancer growth and spread. The study suggests that mutations leading to metastasis often arise early in tumor history, contrary to previous observations.
Researchers have discovered that the act of reading histone modifications leads to the modification of an oncoprotein called TRIM24 with a small protein tag called SUMO. This discovery suggests new ways to inhibit metastasis in cancer cells by targeting TRIM24's interactions with histones.
A new software tool called the automated bone scan index (aBSI) has been shown to be both accurate and speedy in calculating how extensively bones have been infiltrated by prostate cancer. The aBSI technology provided prognostic information about patient outcomes, including survival time and symptom progression.
Researchers identified metarrestin as a compound that stops tumor metastasis in animal models. The compound effectively blocks the spread of pancreatic and other cancers, with mice treated with metarrestin having fewer tumors and living longer.
Scientists have discovered a new compound, metarrestin, that significantly reduces metastasis in human prostate, breast and pancreatic cancer in mice. The compound was found to blow up the complex marker PNC, which indicates cancer cells' ability to spread.
Researchers developed a novel inertial cell focusing and sorting microfluidic device with a wavy channel structure, achieving size-based separation of target cells. The device offers high-throughput, low-energy consumption, and simplified setup, making it suitable for practical biomedical applications.
Researchers have identified a key protein, MIP-1β, that enables ovarian cancer cells to spread through the peritoneal cavity by making mesothelial cells sticky. This discovery could lead to new therapies targeting this protein and its related adhesion protein P-selectin.
A study by UNC Lineberger Comprehensive Cancer Center researchers found that parenting concerns significantly impact the quality of life of mothers with late-stage cancer. The study surveyed 224 mothers and discovered that these concerns contribute as much to their emotional well-being as day-to-day physical functioning does.
Researchers at the University of Montreal have discovered a protein, AXL, that influences the occurrence of metastasis in HER2-positive breast cancers. The study found that reducing AXL levels improves survival rates, and an AXL-inhibiting drug therapy has shown promise in preventing metastases.
Scientists have identified a critical function of the PDK1 signaling pathway in cancer cells, which regulates the formation of a three-protein complex that facilitates purine production and thiamine synthesis. This discovery may lead to new insights into the causes of metastasis and potential ways to prevent it.
A study confirms a curable state between single and widespread cancers by identifying molecular patterns that predict patient outcomes. Researchers found that patients with limited spread of disease could achieve prolonged survival with surgery or targeted radiation therapy.
Researchers at Sanford Burnham Prebys Medical Discovery Institute discovered that PKC zeta deficiency promotes liver metastasis through the inactivation of enzyme ADAR2, leading to increased secretion of miR-200s. Treatment with a compound inhibiting miR-200s reduced liver metastasis in mice with colorectal cancer.
Researchers at UNC Lineberger Comprehensive Cancer Center created tissue-engineered models of metastatic cancer that reflect the microenvironment around tumors. The models, which mimic liver and lung tissues, closely replicate human metastasis characteristics, including 'signet ring cells' linked to poor prognosis.
A microfluidic device developed by Lehigh University engineers can capture and release circulating tumor cells with high efficiency. The device's wavy-herringbone design and magnetic particles allow for selective capture of tumor cells while rejecting unwanted blood cells, enabling early cancer detection and treatment evaluation.
A recent study found that stereotactic radiosurgery (SRS) can improve overall survival and reduce cognitive side-effects in patients with brain metastases from small-cell lung cancer. The study compared outcomes of 5,752 patients who received whole-brain radiation therapy (WBRT) to those of 200 patients who received SRS.
A new BJS study found axillary ultrasound imaging to be less sensitive for detecting axillary metastatic lymph nodes in women with invasive lobular carcinoma compared to invasive ductal carcinoma. Women with invasive lobular carcinoma may benefit from axillary biopsies regardless of ultrasonographic appearance.
Research suggests that bone cells can release signals driving prostate cancer progression and growth, especially when cancer metastasizes to bone. A study found that inhibiting BMP signaling in myeloid cells could restrict cancer cell production and tumor growth.
Researchers used Bio-Rad's Droplet Digital PCR technology to identify potential epigenetic biomarkers for lung cancer recurrence and detect HPV cfDNA in cervical cancer patients. The studies found associations between biomarker levels and treatment outcomes, indicating the clinical utility of ddPCR technology.
New research confirms blood flow plays a crucial role in cancer metastasis by regulating the position of circulating tumor cells and their exit from the vasculature. The study found that slower blood flow rates are associated with increased metastasis development.
IDIBELL researchers discover EphA2 membrane receptor's role in tumor aggressiveness and metastasis in Ewing sarcoma. The study finds that blocking this receptor activity can significantly decrease metastases incidence and survival rates.
Researchers discover microRNA molecule miR-940 that alters bone structure in late-stage prostate cancer. The molecule promotes osteoblastic lesions, which can cause severe pain and structural weakness.
Researchers found that cancer cells from lymph node metastases can invade blood vessels and spread to distant organs like the lung and brain. This study suggests that lymph node metastases could be a source of fatal distant metastases, requiring targeted treatment.
Researchers at the University of Illinois Chicago are developing a small drug molecule that can block JAG1, a cell surface protein found on triple-negative breast cancer cells. The new therapy aims to reduce tumor growth and metastasis, with fewer side effects than aggressive chemotherapy or radiation.
Researchers developed a new approach using biodegradable gels containing immune-stimulating drugs to deliver immunotherapy directly to the surgical site, preventing tumor recurrence and metastasis. The method showed promising results in mice with breast, lung, and melanoma tumors, offering hope for improving cancer treatment outcomes.
Scientists recommend regular brain scans for children with rare liver cancer due to its potential to metastasize. Early detection could increase surgical removal success and inform treatment choices.
Immunotherapy has shown promising results in treating metastatic breast cancer, with a median progression-free survival of 33 months and median overall survival of 82 months. The treatment has been found to improve PFS and OS in both luminal and non-luminal subtypes, offering new hope for patients with this incurable disease.
Researchers established two new adrenal cancer cell lines and mouse models to test novel treatments, identifying PBK as a key target. A patient treated with pembrolizumab showed remarkable response with 77% tumor reduction, while a humanized mouse model also responded to the immunotherapy.
Researchers developed nanoparticles to target liver sinusoidal endothelial cells with miR-20a, restoring normal behavior and reducing tumor growth. The study found an 80% reduction in liver metastasis caused by colon cancer, highlighting a potential complementary treatment strategy.
A new genomic classifier score predicts aggressive prostate cancer, potentially changing treatment guidelines. The model integrates gene expression biomarker risk scores into existing risk groups, increasing accuracy and confidence in treatment recommendations.
Researchers identified genetic patterns in primary and matched metastatic cancers, finding that cells often break away as a collection rather than spreading as a single cell. This insight may lead to better treatments or approaches to prevent its spread at the onset.
Researchers at Purdue University have created a lifelike cancer environment using polymer to better understand how drugs can stop its course. The 3D jet writer device produces polymer microtissues with pore sizes large enough for cells to enter, enabling the simulation of metastasis in mice.
Researchers found elevated mir-24-3p in breast cancer patients destined to metastasize despite best available therapy. High expression of mir-24-3p correlated with poor survival rate and specific gene expression signature in TCGA.
Researchers from DKFZ found that circulating cancer cells exhibit specific polarity, which helps them attach to endothelial cells and migrate into tissues. This discovery may help predict individual risk for metastasis and find therapies to reduce it.
A genetic variant of mutant p53 enhanced mitochondrial function, leading to increased tumor cell metabolism and poorer prognosis for breast cancer patients. The study found that this variant was associated with faster migration and higher ability to invade and metastasize in models of lung and bone metastasis.
Researchers found that repurposed leukemia drugs can inhibit the secretion of pro-metastatic cathepsins in melanoma. This is due to ABL kinases increasing activity, which regulates transcription factors and induces gene expression. The study also showed that approved leukemia drug inhibitors prevent metastasis.
ILC2 cells play a crucial role in preventing or slowing metastasis in lung and prostate cancer by unleashing the killing power of T-cells. Researchers have concluded that ILC2 cells may be a potent weapon in stopping cancer from spreading, offering potential treatment for blood-borne and solid tumours.
Researchers found that genes responsible for metastasis can also initiate primary tumour development, driven by the fly model Drosophila melanogaster. This discovery strengthens the notion that same genes can activate tumour growth and metastasis in some tumours.
The discovery reveals that the enzyme RIPK1 decreases mitochondrial numbers, leading to oxidative stress and potential cell death. This finding could lead to a new strategy for eliminating ECM-detached cancer cells and improving patient survival.
Researchers at Dana-Farber Cancer Institute have identified a specific mechanism by which estrogen receptor-positive breast cancers become resistant to standard therapies and metastasize. DNA mutations in the estrogen receptor gene cause tumors to grow even without estrogen, leading to treatment-resistant disease.
A recent study revealed that patients with inherited DNA repair mutations in metastatic prostate cancer can derive similar benefits from treatment with standard therapies as other patients. Ongoing research explores the potential potency of targeted therapy with PARP inhibitors, which may offer additional therapeutic options for these ...
A phase 3 clinical trial showed apalutamide treatment significantly delayed metastasis development in men with prostate cancer resistant to standard therapy. The treatment also improved survival and reduced disease progression symptoms.
Researchers at The Scripps Research Institute (TSRI) have discovered that levels of a key protein called LTBP3 fuel the chain reaction leading to cancer spread. Lower LTBP3 levels are associated with better prognosis in patients with certain types of cancer, suggesting it as a potential 'upstream' drug target.
A new algorithm provides a comprehensive guide to managing spinal metastases, integrating specialties and offering personalized treatment approaches. The algorithm focuses on spine-specific issues and incorporates popular treatment paths, including surgical decompression and stereotactic body radiotherapy.
The foundation grants nearly $4.1M to support innovative early career researchers and breakthrough scientists conducting basic and translational cancer research. The recipients receive funding to pursue novel projects, with the goal of making paradigm-shifting breakthroughs in cancer prevention, diagnosis, and treatment.
Researchers identified unique mitochondrial defects and alterations in metabolic gene expression associated with aggressive triple-negative breast cancers. The findings provide new molecular biomarkers to identify patients at risk for metastasis and offer potential therapeutic targets.
A recent study published in Nature revealed that gene duplication plays a crucial role in explaining the aggressiveness and early metastasis of pancreatic cancer. Researchers discovered that specific gene amplifications occur along various evolutionary pathways of the cancer, leading to tumor development.
International organizations IASLC and BTOG are partnering to spread awareness of revised lung cancer staging criteria. The new system takes effect this month and aims to provide better care for patients. Key findings highlight improved prognostic factors, tumor size measurements, and coding systems for lung cancers with multiple lesions.
A team of scientists has identified the protein kinase MSK1 as a key regulator of dormant or latent metastases in estrogen-positive breast cancer. The study found that tumors expressing MSK1 have a longer period of latency with no symptoms, reducing the risk of earlier relapse.
A team of researchers has discovered that chromosomal instability can cause cancer cells to leak DNA, leading to a chronic inflammatory response that enables their spread. This finding opens up new possibilities for targeting metastasis in cancer treatment.
Researchers at BIDMC found that high-fat diets can drive metastasis in prostate cancer by suppressing tumor suppressor genes. They identified a key environmental factor driving this process and discovered a potential drug to block it.
Scientists developed a method to analyze lymph node tissue, identifying patients with higher risk of secondary cancers. The study found that analyzing architectural features of cancer-free lymph nodes can help differentiate between patients at high and low risk of metastasis.
Researchers successfully identified pulmonary metastases in a patient with osteosarcoma, making it easier to locate tumors for resection. The technique utilizes targeted fluorescence and binds to specific molecular markers, allowing for the detection of small or hard-to-locate nodules.
Researchers have discovered a key cellular receptor involved in ovarian cancer metastasis, CXCR4, which can be targeted with inhibitors to reduce tumor cell dissemination. High expression of CXCR4 is associated with aggressive variants of the disease.